Recently Viewed
Clear All$12.07
$-0.11
(-0.90%)
As on 24-Mar-2026 16:26EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$3,722 Mln
Revenue (TTM)
$3,019 Mln
Net Profit (TTM)
$0 Mln
ROE
-8.8 %
ROCE
-- %
P/E Ratio
53.8
P/B Ratio
86.1
Industry P/E
--
EV/EBITDA
10.1
Div. Yield
0 %
Debt to Equity
-38.7
Book Value
$--
EPS
$0.2
Face value
--
Shares outstanding
314,629,101
CFO
$1,849.82 Mln
EBITDA
$3,215.23 Mln
Net Profit
$-301.93 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
| -- | -- | -- | 39.4 | 109.6 | 12.4 | -9.3 |
|
BSE Sensex
| -12.5 | -11.1 | -13.4 | -3.7 | 8.5 | 8.2 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
12.1 | 3,722.1 | 3,018.8 | 72.1 | 12.6 | -80 | 53.8 | 86.1 |
| 11.3 | 3,410.4 | 510.2 | 146.9 | 37.2 | 35.6 | 23.9 | 7.2 | |
| 158.8 | 8,027.0 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 92.0 | |
| 68.5 | 13,287.4 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 33.8 | 3,684.8 | 761.4 | 99.7 | 7.3 | 15 | 42.2 | 5.7 | |
| 13.5 | 11,772.8 | 345,831.0 | 56,586.0 | 21.5 | 15.8 | 19.6 | 3.0 | |
| 24.9 | 11,922.1 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.9 | |
| 7.6 | 7,645.3 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.8 | 0.9 | |
| 201.7 | 4,084.1 | 268.1 | 124.5 | 60.0 | 13.5 | 33.5 | 4.0 | |
| 35.2 | 3,208.3 | 158.3 | -68.9 | -29.3 | -113 | -- | 71.7 |
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and... internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey. Read more
Co-Founder, Co-CEO, President & Director
Mr. Chirag K. Patel
Co-Founder, Co-CEO, President & Director
Mr. Chirag K. Patel
Headquarters
Bridgewater, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Amneal Pharmaceuticals Inc Class A (AMRX) is $12.07 (NYSE) and $12.07 (NASDAQ) as of 24-Mar-2026 16:26 EDT. Amneal Pharmaceuticals Inc Class A (AMRX) has given a return of 109.64% in the last 3 years.
The P/E ratio of Amneal Pharmaceuticals Inc Class A (AMRX) is 53.77 times as on 20-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
57.35
|
-58.38
|
|
2024
|
-20.94
|
-22.40
|
|
2023
|
-12.72
|
54.01
|
|
2022
|
-2.31
|
1.01
|
|
2021
|
68.53
|
2.02
|
The 52-week high and low of Amneal Pharmaceuticals Inc Class A (AMRX) are Rs 15.42 and Rs 11.71 as of 25-Mar-2026.
Amneal Pharmaceuticals Inc Class A (AMRX) has a market capitalisation of $ 3,722 Mln as on 20-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Amneal Pharmaceuticals Inc Class A (AMRX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.